Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 19:27 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Safety and Efficacy of Milnacipran in Pediatric Patients With Primary Fibromyalgia
NCT01328002 · Forest Laboratories · PHASE2 · terminated · last registry update 2019-05-14 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, Forest Laboratories |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against SLC6A4 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2020-04-14Phase 3 first posted: Mochida Pharmaceutical Company, Ltd., Desvenlafaxine 100 mg + Desvenlafaxine 50 mg (NCT04345471)
- 2020-03-10Phase 3 first posted: University of Edinburgh, Memantine Hydrochloride Oral Solution + Trazodone Hydrochloride oral solution (NCT04302870)
- 2020-02-26Phase 3 first posted: Intra-Cellular Therapies, Inc., Lumateperone + Placebos (NCT04285515)
- 2019-05-21Results posted on the registry: Janssen Research & Development, LLC, Esketamine + Placebo (NCT02493868)
- 2019-04-29Results posted on the registry: Janssen Research & Development, LLC, Esketamine (Intranasal Spray) + Duloxetine (Oral Antidepressant) (NCT02497287)
- 2019-04-24Results posted on the registry: Janssen Research & Development, LLC, Esketamine + Placebo (NCT02422186)
- 2019-04-19Results posted on the registry: Janssen Research & Development, LLC, Esketamine + Placebo (NCT02418585)
- 2019-04-18Results posted on the registry: Janssen Research & Development, LLC, Esketamine + Placebo (NCT02417064)
- 2019-04-10Results posted on the registry: University of California, Los Angeles, Venlafaxine (Effexor), Duloxetine (Cymbalta), Escitalopram (Lexapro) (NCT00200902)
- 2019-04-09Phase 3 first posted: The University of Hong Kong, Escitalopram + Insomnia medication (NCT03909217)
- 2019-02-25Phase 3 first posted: Janssen-Cilag International NV, Esketamine 28 mg + Esketamine 56 mg (NCT03852160)
- 2018-09-12Phase 3 first posted: VA Office of Research and Development, Trazodone + Eszopiclone (NCT03668041)
- 2018-08-29Phase 3 first posted: Maastricht University Medical Center, Nortriptyline + Placebo (NCT03652571)
- 2018-05-23Phase 3 first posted: University of Washington, Trazodone + Placebo (NCT03534284)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision